FDA warned telehealth seller NativeMed that its website misbranded compounded semaglutide and tirzepatide with false or misleading claims.
What happened
FDA reviewed NativeMed's website, https://www.nativemed.net, in March 2026 and found it offering compounded semaglutide and tirzepatide drug products. The site showed tirzepatide products with NativeMed's logo on the pictured label, which suggests NativeMed made the drugs when it did not, and stated that its compounded semaglutide contains "The same active ingredient in Ozempic® and Wegovy®." FDA said these representations make the products misbranded (labeling or promotion that is false or misleading) and that shipping them across state lines is a prohibited act.
What FDA found
The website showed tirzepatide products with NativeMed's logo on the label, implying NativeMed is the maker when it is not.
21 C.F.R. § 201.1(h)(2); FD&C Act § 502(a) [21 U.S.C. § 352(a)]The claim that the compounded semaglutide has the same active ingredient as Ozempic® and Wegovy® implies FDA approval or evaluation that the compounded products do not have.
FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Because of these claims, the products are misbranded and were introduced into interstate commerce, which is a prohibited act.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]Compounded drugs must meet the conditions of section 503A or 503B to be exempt from the new drug approval requirements.
FD&C Act §§ 503A and 503B [21 U.S.C. §§ 353a, 353b]
What FDA wants
FDA asks NativeMed to identify the entities that actually make the compounded drugs it offers, provide sample labeling, and correct or remove the misleading website claims. The company must send its written response to FDA within 15 business days.
Who should pay attention
- telehealth and online sellers of compounded GLP-1 drugs
- compounding pharmacies whose products are marketed on third-party websites
- marketing and affiliate partners that write claims for compounded drugs
This is a summary. Read the original letter on fda.gov.